Press coverage about Atara Biotherapeutics (NASDAQ:ATRA) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.775097392557 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
ATRA has been the subject of several recent research reports. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday. Jefferies Group LLC reissued a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a report on Friday, October 6th. Finally, BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.40.
Atara Biotherapeutics (ATRA) traded up $0.25 during trading on Friday, hitting $13.45. The stock had a trading volume of 326,800 shares, compared to its average volume of 162,627. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $23.00.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). equities research analysts predict that Atara Biotherapeutics will post -3.99 earnings per share for the current fiscal year.
In related news, CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $15.54, for a total value of $68,376.00. Following the completion of the transaction, the chief executive officer now directly owns 737,767 shares in the company, valued at approximately $11,464,899.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Christopher Haqq sold 7,604 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $14.75, for a total value of $112,159.00. Following the completion of the transaction, the executive vice president now owns 362,909 shares of the company’s stock, valued at $5,352,907.75. The disclosure for this sale can be found here. Insiders have sold a total of 52,209 shares of company stock valued at $763,857 over the last 90 days. Corporate insiders own 16.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics (ATRA) Receives Coverage Optimism Rating of 0.11” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/12/atara-biotherapeutics-atra-receives-coverage-optimism-rating-of-0-11.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.